Exposure to anti‐PD‐1 causes functional differences in tumor‐infiltrating lymphocytes in rare solid tumors
Open Access
- 18 September 2019
- journal article
- research article
- Published by Wiley in European Journal of Immunology
- Vol. 49 (12) , 2245-2251
Abstract
The pervasive use of therapeutic antibodies targeting programmed cell death protein 1 (PD‐1) to boost anti‐tumor immunity has positioned this approach to become the standard‐of‐care for some solid tumor malignancies. However, little is known as to how blockade of PD‐1 may alter the function or phenotype of tumor‐infiltrating lymphocytes (TIL). We used our ongoing Phase II clinical trial of pembrolizumab for patients with rare solid tumors from various types (NCT02721732) with matched core biopsies taken at baseline and after initial dose of anti‐PD‐1 (15–21 days post‐dose) to elucidate this question. One fresh core needle biopsy was used to propagate TIL ex vivo to analyze phenotype and function using flow cytometry in both CD8+ and CD4+ TIL populations. An enriched CTLA‐4 expression in the CD4+ TIL population was observed in TIL expanded from the on‐treatment samples compared to TIL expanded from the matched baseline (n = 22, p = 0.0007) but was not observed in patients who experienced tumor regression. Impact on functionality was evaluated by measuring secretion of 65 soluble factors by expanded TIL from 26 patients at baseline and on‐treatment. The CD8+ TIL population demonstrated a diminished cytokine secretion profile post‐pembrolizumab. Overall, our study assesses the ramifications of one dose of anti‐PD‐1 on TIL in rare solid tumor types.Keywords
This publication has 24 references indexed in Scilit:
- CTLA-4 and PD-1 PathwaysAmerican Journal of Clinical Oncology, 2016
- VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumorsJournal of Experimental Medicine, 2015
- Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25Cell Research, 2015
- The neurotrophic hepatocyte growth factor attenuates CD8+ cytotoxic T-lymphocyte activityJournal of Neuroinflammation, 2013
- Increased Tc22 and Treg/CD8 Ratio Contribute to Aggressive Growth of Transplant Associated Squamous Cell CarcinomaPLOS ONE, 2013
- Co-Stimulation through 4-1BB/CD137 Improves the Expansion and Function of CD8+ Melanoma Tumor-Infiltrating Lymphocytes for Adoptive T-Cell TherapyPLOS ONE, 2013
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumorsProceedings of the National Academy of Sciences, 2010
- IL-23 Drives Pathogenic IL-17-Producing CD8+ T CellsThe Journal of Immunology, 2009
- CXCL12 Induction of Inducible Nitric Oxide Synthase in Human CD8 T CellsThe Journal of Heart and Lung Transplantation, 2008
- Anti-CTLA4 antibody clinical trials in melanomaUpdate on Cancer Therapeutics, 2007